Guy Gammon

4.4k total citations
64 papers, 3.4k citations indexed

About

Guy Gammon is a scholar working on Hematology, Immunology and Genetics. According to data from OpenAlex, Guy Gammon has authored 64 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Hematology, 26 papers in Immunology and 23 papers in Genetics. Recurrent topics in Guy Gammon's work include Acute Myeloid Leukemia Research (28 papers), Chronic Myeloid Leukemia Treatments (26 papers) and Chronic Lymphocytic Leukemia Research (20 papers). Guy Gammon is often cited by papers focused on Acute Myeloid Leukemia Research (28 papers), Chronic Myeloid Leukemia Treatments (26 papers) and Chronic Lymphocytic Leukemia Research (20 papers). Guy Gammon collaborates with scholars based in United States, United Kingdom and France. Guy Gammon's co-authors include Eli E. Sercarz, Denise Trone, Colin Dayan, Thomas G. Forsthuber, Paul Lehmann, Jörge E. Cortes, Mark J. Levis, Nilabh Shastri, Donald L. Morton and Alexander E. Perl and has published in prestigious journals such as Nature, Science and The Journal of Experimental Medicine.

In The Last Decade

Guy Gammon

63 papers receiving 3.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Guy Gammon United States 28 1.6k 1.1k 1.0k 756 399 64 3.4k
P Mannoni France 32 1.3k 0.8× 1.2k 1.1× 1.5k 1.4× 634 0.8× 447 1.1× 128 3.5k
J F Daley United States 35 3.2k 2.0× 930 0.8× 603 0.6× 921 1.2× 541 1.4× 57 4.7k
Martin Corcoran Sweden 35 999 0.6× 2.1k 1.9× 446 0.4× 521 0.7× 892 2.2× 72 3.9k
Jerry W. Slootstra Netherlands 19 737 0.5× 1.0k 0.9× 634 0.6× 826 1.1× 467 1.2× 35 2.5k
Beverley L. Pike Australia 25 1.6k 1.0× 607 0.5× 755 0.7× 437 0.6× 278 0.7× 59 2.8k
Graham P. Cook United Kingdom 28 1.6k 1.0× 1.1k 1.0× 365 0.4× 713 0.9× 239 0.6× 65 2.9k
Kunihiro Hattori Japan 29 757 0.5× 1.1k 1.0× 873 0.8× 544 0.7× 359 0.9× 75 2.9k
Wasif N. Khan United States 32 2.6k 1.6× 1.0k 0.9× 362 0.3× 540 0.7× 813 2.0× 69 3.9k
Patricia A. Temple United States 8 1.8k 1.1× 929 0.8× 737 0.7× 674 0.9× 129 0.3× 8 3.4k
Gregory R. Johnson Australia 26 907 0.6× 822 0.7× 719 0.7× 449 0.6× 287 0.7× 55 2.4k

Countries citing papers authored by Guy Gammon

Since Specialization
Citations

This map shows the geographic impact of Guy Gammon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guy Gammon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guy Gammon more than expected).

Fields of papers citing papers by Guy Gammon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guy Gammon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guy Gammon. The network helps show where Guy Gammon may publish in the future.

Co-authorship network of co-authors of Guy Gammon

This figure shows the co-authorship network connecting the top 25 collaborators of Guy Gammon. A scholar is included among the top collaborators of Guy Gammon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guy Gammon. Guy Gammon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ganguly, Siddhartha, Jörge E. Cortes, Alwin Krämer, et al.. (2020). Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial. Transplantation and Cellular Therapy. 27(2). 153–162. 22 indexed citations
3.
Cooper, Todd M., Elena Eckroth, Jemily Malvar, et al.. (2016). A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clinical Cancer Research. 22(16). 4014–4022. 56 indexed citations
4.
5.
Morton, Donald L., Eddy C. Hsueh, Richard Essner, et al.. (2002). Prolonged Survival of Patients Receiving Active Immunotherapy With Canvaxin Therapeutic Polyvalent Vaccine After Complete Resection of Melanoma Metastatic to Regional Lymph Nodes. Annals of Surgery. 236(4). 438–449. 117 indexed citations
6.
Rawlins, Philip B., Roya Sadeghi, Guy Gammon, et al.. (1999). Inhibition of endotoxin-induced TNF-α production in macrophages by 5Z-7-oxo-zeaenol and other fungal resorcylic acid lactones. International Journal of Immunopharmacology. 21(12). 799–814. 22 indexed citations
7.
Ollila, David W., Mark C. Kelley, Guy Gammon, & Donald L. Morton. (1998). Overview of melanoma vaccines: Active specific immunotherapy for melanoma patients. Seminars in Surgical Oncology. 14(4). 328–336. 32 indexed citations
8.
Ollila, David W., et al.. (1997). Update on active specific immunotherapy with melanoma vaccines. Journal of Surgical Oncology. 66(1). 55–64. 20 indexed citations
9.
Hughes, Anne E., Philip B. Rawlins, Christopher E Clark, et al.. (1997). Differential effects on TNFα production by pharmacological agents with varying molecular sites of action. International Journal of Immunopharmacology. 19(8). 451–462. 14 indexed citations
10.
Brown, Diane E., et al.. (1995). Detection of interleukin-1 signal transduction inhibitors: Action of protein kinase inhibitors. International Journal of Immunopharmacology. 17(11). 887–894. 4 indexed citations
11.
Gammon, Guy, et al.. (1994). Complications in the Functional Analysis of Transfected MHC Genes. Cellular Immunology. 154(1). 219–230. 3 indexed citations
12.
Lehmann, Paul, Eli E. Sercarz, Thomas G. Forsthuber, Colin Dayan, & Guy Gammon. (1993). Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunology Today. 14(5). 203–208. 396 indexed citations
13.
Depledge, Paul, Stephen K. Wrigley, Jan Mous, et al.. (1993). CD4-binding compounds: An assay to detect new classes of immunopharmacological agents. International Journal of Immunopharmacology. 15(3). 361–369. 4 indexed citations
14.
Gammon, Guy, H. Mario Geysen, R. Apple, et al.. (1991). T cell determinant structure: cores and determinant envelopes in three mouse major histocompatibility complex haplotypes.. The Journal of Experimental Medicine. 173(3). 609–617. 119 indexed citations
15.
Gammon, Guy, Eli E. Sercarz, & Gilles Bénichou. (1991). The dominant self and the cryptic self: shaping the autoreactive T-cell repertoire. Immunology Today. 12(6). 193–195. 95 indexed citations
16.
Gammon, Guy & Eli E. Sercarz. (1990). Does the presence of self-reactive T cells indicate the breakdown of tolerance?. Clinical Immunology and Immunopathology. 56(3). 287–297. 19 indexed citations
17.
Gammon, Guy & Eli E. Sercarz. (1989). How some T cells escape tolerance induction. Nature. 342(6246). 183–185. 178 indexed citations
18.
Ametani, Akio, R. Apple, V Bhardwaj, et al.. (1989). Examining the Crypticity of Antigenic Determinants. Cold Spring Harbor Symposia on Quantitative Biology. 54(0). 505–511. 14 indexed citations
19.
Gammon, Guy, Nilabh Shastri, John Cogswell, et al.. (1987). The Choice of T‐Cell Epitopes Utilized on a Protein Antigen Depends on Multiple Factors Distant from, as well as at the Determinant Site. Immunological Reviews. 98(1). 54–73. 221 indexed citations
20.
Shastri, Nilabh, Guy Gammon, Austin Miller, & Eli E. Sercarz. (1986). Ia molecule-associated selectivity in T cell recognition of a 23-amino-acid peptide of lysozyme.. The Journal of Experimental Medicine. 164(3). 882–896. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P Mannoni Breakdown of academic impact, for papers by J F Daley Breakdown of academic impact, for papers by Martin Corcoran Breakdown of academic impact, for papers by Jerry W. Slootstra Breakdown of academic impact, for papers by Beverley L. Pike Breakdown of academic impact, for papers by Graham P. Cook Breakdown of academic impact, for papers by Kunihiro Hattori Breakdown of academic impact, for papers by Wasif N. Khan Breakdown of academic impact, for papers by Patricia A. Temple Breakdown of academic impact, for papers by Gregory R. Johnson
Rankless by CCL
2026